Novartis AG News and Pharmaceutical & Life Sciences Updates

Novartis AG (NVS) rallied 3.33% after raising its 2026 core operating income guidance and disclosing FDA approval for LAMPRENE, which lifted sentiment and drove today's gain. The move is supported ...

Novartis is defending remibrutinib as a potential major growth driver as investors look beyond the company’s recent recovery from patent losses. Questions over the drug’s efficacy in relapsing ...

Novartis is absorbing a major impairment charge after a late-stage setback for a rare disease treatment tied to its biggest acquisition in more than a decade. The Swiss drugmaker is nevertheless ...

U.S. stocks start the holiday-shortened week lower as rising oil prices and bond yields weigh on broader indexes, while healthcare shares come under added pressure from clinical trial ...

Premarket trading is highlighting a mix of earnings-driven gains and selective declines across large-cap industrial, healthcare and consumer names. Novartis, General Motors and MMM are advancing ...

Novartis is expanding its cancer drug portfolio with an agreement to acquire London-based Myricx Bio for up to $1.5 billion. The transaction adds a UK oncology biotech spun out of Imperial College ...

Novartis AG (NVS) stock is trading at $147.78, down 2.06% on the day and ending near the session low. The price has moved below its key short- and medium-term moving ...

Novartis AG (NVS) is trading at $147.38 after declining $3.50 (2.32%) today. The asset is positioned below both the 20-day moving average ($149.61) and 50-day moving average ($149.08), though it ...